AstraZeneca and MSD’s Lynparza is a step closer to being cleared in Europe as maintenance therapy for some patients with ovarian cancer.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.